Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies  

作　　者：Zhenan Deng Meiling Jin Changxing Ou Wei Jiang Jianping Zhao Xiaoxia Liu Shenghua Sun Huaping Tang Bei He Shaoxi Cai Ping Chen Penghui Wu Yujing Liu Jian Kang Yunhui Zhang Mao Huang Jinfu Xu Kewu Huang Qiang Li Xiangyan Zhang Xiuhua Fu Changzheng Wang Huahao Shen Lei Zhu Guochao Shi Zhongmin Qiu Zhongguang Wen Xiaoyang Wei Wei Gu Chunhua Wei Guangfa Wang Ping Chen Lixin Xie Jiangtao Lin Yuling Tang Zhihai Han Kian Fan Chung Qingling Zhang Nanshan Zhong C-BIOPRED Consortium 

机构地区：[1]Pulmonary and Critical Care Medicine,Guangzhou Institute of Respiratory Health,National Clinical Research Center for Respiratory Disease,National Center for Respiratory Medicine,State Key Laboratory of Respiratory Diseases,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510120,China [2]Department of Respiratory Medicine,Zhongshan Hospital,Shanghai 200433,China [3]Guangzhou Medical University,Guangzhou,Guangdong 510180,China [4]AstraZeneca,Shanghai 200085,China [5]Department of Respiratory Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China [6]Department of Respiratory Medicine,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China [7]Department of Respiratory Medicine,The Third Xiangya Hospital of Central South University,Changsha,Hunan 410013,China [8]Department of Respiratory Medicine,Qingdao Municipal Hospital,Qingdao,Shandong 266001,China [9]Department of Respiratory Medicine,Peking University Third Hospital,Beijing 100191,China [10]Department of Respiratory Medicine,Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong 510515,China [11]Department of Respiratory Medicine,General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,China [12]Department of Respiratory Medicine,The First Hospital of China Medical University,Shenyang,Liaoning 110001,China [13]Department of Respiratory Medicine,The First people’s Hospital of Yunnan Province,Kunming,Yunnan 363880,China [14]Department of Respiratory Medicine,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China [15]Department of Respiratory Medicine,Shanghai Pulmonary Hospital,Shanghai 200433,China [16]Department of Respiratory Medicine,Beijing Chao-Yang Hospital,Beijing 100020,China [17]Department of Respiratory Medicine,Shanghai General Hospital,Shanghai 200080,China [18]Department of Respiratory Medicine,Guizhou Province People’s Hospital,Guiyang,Guizhou 550002,China [19]Departme

出　　处：《Chinese Medical Journal》2023年第2期230-232,共3页中华医学杂志（英文版）

基　　金：supported by grants from AstraZeneca,China,and the National Natural Science Foundation of China(No.82070026).

摘　　要：To the Editor:Patients with severe persistent asthma experience greater morbidity with more impairment in quality of life despite higher use of health care resources and being treated with existing asthma treatments such as inhaled corticosteroids and b-agonists,and sometimes oral corticosteroid(OCS)therapy.Type-2(T2)high asthma has been identified as a phenotype that responds to targeted T2 biologic therapies such as anti-IgE,anti-interleukin(IL)5,or anti-IL5Ra and anti-IL4Ra monoclonal antibodies,which are currently available in Europe and North America,and are currently introduced in the rest of the world.[1]

关 键 词：ASTHMA THERAPIES IMPAIRMENT 

分 类 号：R562.25[医药卫生—呼吸系统]